$ELOX
Eloxx Pharmaceuticals, Inc.

2018 Q4 Form 10-K Financial Statement

#000156459019007811 Filed on March 14, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2017 Q4 2017
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.580M $2.870M $3.990M
YoY Change 164.11% 856.67% 147.83%
% of Gross Profit
Research & Development $6.530M $8.400M $16.40M
YoY Change -22.26% 3900.0% 82.48%
% of Gross Profit
Depreciation & Amortization $100.0K $30.00K $39.00K
YoY Change 233.33% 50.0% 387.5%
% of Gross Profit
Operating Expenses $14.11M $8.400M $20.39M
YoY Change 67.98% 456.29% 107.22%
Operating Profit -$20.39M
YoY Change 107.22%
Interest Expense $2.380M -$74.00
YoY Change 2544.44% -86.12%
% of Operating Profit
Other Income/Expense, Net $210.0K $640.0K -$824.0K
YoY Change -67.19% 190.91% 11671.43%
Pretax Income -$13.91M -$15.87M -$21.21M
YoY Change -12.35% 1233.61% 115.44%
Income Tax $120.0K $0.00 -$640.0K
% Of Pretax Income
Net Earnings -$14.03M -$10.60M -$21.21M
YoY Change 32.36% 1241.77% 115.44%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$397.6K -$1.033M -$4.259M
COMMON SHARES
Basic Shares Outstanding 35.86M 27.53M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.61M $24.05M $24.05M
YoY Change 102.12% 15933.33% 2869.14%
Cash & Equivalents $48.61M $24.05M $24.05M
Short-Term Investments
Other Short-Term Assets $1.740M $460.0K $460.0K
YoY Change 278.26% 820.0% 170.59%
Inventory
Prepaid Expenses $267.0K
Receivables
Other Receivables
Total Short-Term Assets $50.34M $24.51M $24.51M
YoY Change 105.42% 693.85% 2401.02%
LONG-TERM ASSETS
Property, Plant & Equipment $248.0K $278.0K $280.0K
YoY Change -10.79% 578.05% 211.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $129.0K
YoY Change
Total Long-Term Assets $377.0K $278.0K $270.0K
YoY Change 35.61% 578.05% -96.73%
TOTAL ASSETS
Total Short-Term Assets $50.34M $24.51M $24.51M
Total Long-Term Assets $377.0K $278.0K $270.0K
Total Assets $50.72M $24.78M $24.78M
YoY Change 104.64% 692.33% 168.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $747.0K $1.530M $1.530M
YoY Change -51.18% -19.43% 1600.0%
Accrued Expenses $6.938M $1.893M $1.890M
YoY Change 266.51% 205.82% 626.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.807M $3.423M $3.420M
YoY Change 128.07% 35.94% 824.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.807M $3.423M $3.420M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $7.807M $3.420M $3.420M
YoY Change 128.27% 15.54% -26.77%
SHAREHOLDERS EQUITY
Retained Earnings -$86.15M -$38.96M
YoY Change 121.11% 119.54%
Common Stock $130.2M $60.32M
YoY Change 115.82% 229.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.91M $21.36M $21.36M
YoY Change
Total Liabilities & Shareholders Equity $50.72M $24.78M $24.78M
YoY Change 104.64% 692.33% 168.47%

Cashflow Statement

Concept 2018 Q4 2017 Q4 2017
OPERATING ACTIVITIES
Net Income -$14.03M -$10.60M -$21.21M
YoY Change 32.36% 1241.77% 115.44%
Depreciation, Depletion And Amortization $100.0K $30.00K $39.00K
YoY Change 233.33% 50.0% 387.5%
Cash From Operating Activities -$9.060M $6.300M -$15.94M
YoY Change -243.81% -1531.82% 80.18%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$240.0K $237.0K
YoY Change -54.17% 558.33%
Acquisitions
YoY Change
Other Investing Activities -$70.00K $60.00K $60.00K
YoY Change -216.67%
Cash From Investing Activities -$180.0K -$180.0K -$114.0K
YoY Change 0.0% 216.67%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change
Common Stock Issuance & Retirement, Net $17.01M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.500M 36.45M 37.95M
YoY Change -93.14% 12050.0% 289.79%
NET CHANGE
Cash From Operating Activities -9.060M 6.300M -15.94M
Cash From Investing Activities -180.0K -180.0K -114.0K
Cash From Financing Activities 2.500M 36.45M 37.95M
Net Change In Cash -6.740M 6.300M 21.90M
YoY Change -206.98% -4600.0% 2458.53%
FREE CASH FLOW
Cash From Operating Activities -$9.060M $6.300M -$15.94M
Capital Expenditures -$110.0K -$240.0K $237.0K
Free Cash Flow -$8.950M $6.540M -$16.17M
YoY Change -236.85% -1586.36% 82.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
274000
CY2018Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1129000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1690000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
355000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
50341000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
24506000
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48606000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24049000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
45000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
102000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
278000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
129000
CY2018Q4 us-gaap Assets
Assets
50718000
CY2017Q4 us-gaap Assets
Assets
24784000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
747000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1530000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6938000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
122000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7807000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3423000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
360000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129825000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60047000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86145000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38960000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
42911000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21361000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50718000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24784000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 dei Entity Public Float
EntityPublicFloat
247531848
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35860114
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2017 elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
1290000
CY2018 us-gaap Operating Expenses
OperatingExpenses
47565000
CY2017 us-gaap Operating Expenses
OperatingExpenses
20390000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-47565000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-9847000
CY2017 elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-2404000
CY2016 elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-1100000
CY2018 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-47185000
CY2017 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-23618000
CY2016 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-10947000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35951537
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27527738
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35860114
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27527738
CY2018Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
91423
CY2017Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20489000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16398000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8986000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26482000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2702000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
854000
CY2018 elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
594000
CY2016 us-gaap Operating Expenses
OperatingExpenses
9840000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-20390000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-9840000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
502000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-824000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47063000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21214000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9847000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
122000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-47185000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-21214000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.75
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.60
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32436506
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4976377
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4205277
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
643000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
78000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
610000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
101000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17006000
CY2017 elox Stock Issued During Period Value Reverse Acquisitions
StockIssuedDuringPeriodValueReverseAcquisitions
170000
CY2017 elox Adjustments To Additional Paid In Capital Provision For Exit Fees
AdjustmentsToAdditionalPaidInCapitalProvisionForExitFees
3416000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
446000
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
31000
CY2018 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-1046000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
13370000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
494000
CY2018 us-gaap Profit Loss
ProfitLoss
-47185000
CY2017 us-gaap Profit Loss
ProfitLoss
-21214000
CY2016 us-gaap Profit Loss
ProfitLoss
-9847000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
13370000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
101000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
78000
CY2016 us-gaap Depreciation
Depreciation
8000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
668000
CY2017 elox Provision For Exit Fees
ProvisionForExitFees
3416000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1080000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-709000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
482000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
41000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-780000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-583000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1250000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3999000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
929000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
149000
CY2018 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
122000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31367000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15935000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8844000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
235000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
CY2018 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
88000
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
123000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-317000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36000
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
350000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
446000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
CY2016 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
9386000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17006000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2500000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56184000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37950000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9736000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24500000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21901000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
856000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24151000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2250000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1394000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48651000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2212000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
45000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
102000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
38000
CY2018 elox Noncash Acquisition Of Treasury Shares
NoncashAcquisitionOfTreasuryShares
1129000
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3168000
CY2018 elox Non Cash Acquisition Of Shares From Equity Sales Agreement
NonCashAcquisitionOfSharesFromEquitySalesAgreement
255000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1341000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These classification had no effected on the previously report net loss.</p>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates estimates on an ongoing basis in light of changes in circumstances, facts and experiences. Actual results could materially differ from those estimates. </p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash. Substantially all of the Company&#8217;s cash is held at financial institutions that management believes to be of high-credit quality. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. </p>
CY2018 us-gaap Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Grants </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received royalty-bearing grants to Eloxx Limited for the years ended 2015 to 2017 totaling $2.6 million, which represents participation in approved research and development programs of the Israeli Innovation Authority (&#8220;IIA&#8221;) (previously known as the Office of the Chief Scientist of the Ministry of Economy). These amounts are recognized on the accrual basis as a reduction of research and development expenses as such expenses are incurred. </p>
CY2018 elox Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons
NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons
1800
CY2018 elox Number Of Novel Ersg Drug Candidates
NumberOfNovelERSGDrugCandidates
170
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018 us-gaap Payments Of Dividends
PaymentsOfDividends
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018 us-gaap Dividends
Dividends
0
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
251000
CY2018Q4 elox Contract Receivable Current
ContractReceivableCurrent
20000
CY2017Q4 elox Contract Receivable Current
ContractReceivableCurrent
88000
CY2018Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
864000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
555000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
267000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
452000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
204000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2562000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
402000
CY2018Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3086000
CY2017Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
704000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
985000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
541000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
490000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
310000
CY2018Q4 elox Class Of Warrant Or Right Exercisable In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableInPeriodWeightedAverageExercisePrice
3.77
CY2017 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y2M26D
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2016Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
6000000
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0.1
CY2016Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3700000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
480049
CY2018 elox Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
64374
CY2018 elox Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
68434
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
347241
CY2018Q4 elox Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
347241
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.97
CY2018 elox Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
0.80
CY2018 elox Class Of Warrant Or Right Forfeited In Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedInPeriodWeightedAverageExercisePrice
8.00
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.77
CY2018 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P3Y11M1D
CY2018 elox Class Of Warrant Or Right Exercisable Expiration Period
ClassOfWarrantOrRightExercisableExpirationPeriod
P3Y11M1D
CY2018Q2 elox Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
2
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3215661
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1711881
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1334522
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
331301
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1019835
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.91
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.06
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.34
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.66
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.26
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M3D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M21D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20479722
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11650373
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6598055
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18700000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M10D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.06
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.68
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.14
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.903
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8717
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6446
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.92
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1669
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0557
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0255
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0122
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0047
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.032
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0235
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2017 elox Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0.10
CY2016 elox Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0.10
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.3
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.3
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.3
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13370000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
101000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
78000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-24439000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
44000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22624000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21145000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-9883000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-47063000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-21166000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9839000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
94000
CY2018 elox Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0.10
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
28000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29521000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23689000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1001000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1125000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
377000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
11000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
714000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
714000
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4216000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2604000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
40000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35869000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28143000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35869000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28143000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7700000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24100000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.024
CY2018 elox Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.030
CY2018 elox Effective Income Tax Rate Reconciliation Adjustments To Deferred Taxes
EffectiveIncomeTaxRateReconciliationAdjustmentsToDeferredTaxes
-0.018
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.008
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.001
CY2018 elox Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActChangeInValuationAllowancePercent
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.195
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
700000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
700000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10200000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
700000
CY2018 us-gaap Interest And Other Income
InterestAndOtherIncome
601000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-92000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-156000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7000
CY2018 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company is subject to income taxes in the United States and Israel. The Company files income tax return in the United States and in several states. The federal and state tax returns are generally subject to tax examination by taxing authorities for tax years beginning in June 30, 2015 to present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Israeli income tax returns remain open to examination beginning in 2013 to present. If and when the Company claims NOL carryforwards from any prior years against future taxable income, those losses may be examined by the taxing authorities.
CY2018 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2017 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2016 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4163107
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19027306
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12746823
CY2017 elox Amortization Of Debt Discount Premiums
AmortizationOfDebtDiscountPremiums
625000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
43000
CY2018 us-gaap Interest Expense Other
InterestExpenseOther
7000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 elox Number Of Geographic Regions
NumberOfGeographicRegions
2

Files In Submission

Name View Source Status
0001564590-19-007811-index-headers.html Edgar Link pending
0001564590-19-007811-index.html Edgar Link pending
0001564590-19-007811.txt Edgar Link pending
0001564590-19-007811-xbrl.zip Edgar Link pending
elox-10k_20181231.htm Edgar Link pending
elox-20181231.xml Edgar Link completed
elox-20181231.xsd Edgar Link pending
elox-20181231_cal.xml Edgar Link unprocessable
elox-20181231_def.xml Edgar Link unprocessable
elox-20181231_lab.xml Edgar Link unprocessable
elox-20181231_pre.xml Edgar Link unprocessable
elox-ex1038_388.htm Edgar Link pending
elox-ex1040_659.htm Edgar Link pending
elox-ex211_387.htm Edgar Link pending
elox-ex231_386.htm Edgar Link pending
elox-ex232_718.htm Edgar Link pending
elox-ex311_29.htm Edgar Link pending
elox-ex312_28.htm Edgar Link pending
elox-ex321_26.htm Edgar Link pending
elox-ex322_27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwvatmrhfi3s000001.jpg Edgar Link pending
gwvatmrhfi3s000002.jpg Edgar Link pending
gwvatmrhfi3s000003.jpg Edgar Link pending
gwvatmrhfi3s000004.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending